

## DESCRIPTION



<b>Species Reactivity</b>	Human
<b>Specificity</b>	Detects human Glypican 1 in direct ELISAs and Western blots. In direct ELISAs and Western blots, approximately 15% cross-reactivity with recombinant mouse Glypican 1 is observed and less than 1% cross-reactivity with recombinant human (rh) Glypican 5 and rhGlypican 6 is observed.
<b>Source</b>	Polyclonal Goat IgG
<b>Purification</b>	Antigen Affinity-purified
<b>Immunogen</b>	Mouse myeloma cell line NS0-derived recombinant human Glypican 1 Asp24-Ser530 Accession # P35052
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.

## APPLICATIONS

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	<b>Recommended Concentration</b>	<b>Sample</b>
<b>Western Blot</b>	0.1 µg/mL	Recombinant Human Glypican 1 (Catalog # 4519-GP)
<b>Flow Cytometry</b>	2.5 µg/10 <sup>6</sup> cells	See Below
<b>Immunocytochemistry</b>	5-15 µg/mL	See Below
<b>CyTOF-ready</b>	Ready to be labeled using established conjugation methods. No BSA or other carrier proteins that could interfere with conjugation.	

## DATA

<p><b>Flow Cytometry</b></p>  <p><b>Detection of Glypican 1 in MDA-MB-231 Human Cell Line by Flow Cytometry.</b> MDA-MB-231 human breast cancer cell line was stained with Goat Anti-Human Glypican 1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4519, filled histogram) or isotype control antibody (Catalog # AB-108-C, open histogram), followed by Phycoerythrin-conjugated Anti-Goat IgG Secondary Antibody (Catalog # F0107).</p>	<p><b>Immunocytochemistry</b></p>  <p><b>Glypican 1 in MDA-MB-231 Human Cell Line.</b> Glypican 1 was detected in immersion fixed MDA-MB-231 human breast cancer cell line using Goat Anti-Human Glypican 1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF4519) at 10 µg/mL for 3 hours at room temperature. Cells were stained using the NorthernLights™ 557-conjugated Anti-Goat IgG Secondary Antibody (red; Catalog # NL001) and counterstained with DAPI(blue). Specific staining was localized to cytoplasmic. View our protocol for <a href="#">Fluorescent ICC Staining of Cells on Coverslips</a>.</p>
---	---

## PREPARATION AND STORAGE

<b>Reconstitution</b>	Reconstitute at 0.2 mg/mL in sterile PBS.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
<b>Stability &amp; Storage</b>	<b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"> <li>● 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>● 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>● 6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

**BACKGROUND**

The Glypicans (*glypiated proteoglycans*) are a small multigene family of GPI-linked proteoglycans that play a key role in growth factor signaling (1, 2, 3, 4). There are six known mammalian Glypicans. They all share a common-sized protein core of 60-70 kDa, an N-terminus which likely forms a compact globular domain, 14 conserved cysteines that form multiple intrachain disulfide bonds, and a number of C-terminal N- and O-linked carbohydrate attachment sites. Based on exon organization and the location of O-linked glycosylation sites, at least two subfamilies of Glypicans are known, with one subfamily containing Glypicans 1, 2, 4 and 6, and another subfamily containing Glypicans 3 and 5 (3, 5). Human Glypican 1 (GPC-1) is synthesized as a 558 amino acid (aa) preproprecursor that contains a 23 aa signal sequence, a 507 aa mature segment, and a 28 aa C-terminal prosegment (6, 7). There are two potential N-linked and four potential O-linked sites for glycosylation or glycanation. There are potentially two heparan sulfate (HS) modifications on GPC-1 that could contribute to a native molecular weight of approximately 200 kDa (7, 8, 9). Mature human GPC-1 shares 91% aa identity with mature mouse GPC-1. There are two potential splice variants of human GPC-1. Both show an alternate start site at Met73, while one has an additional 65 aa substitution for the C-terminal 264 amino acids (10, 11). Cells known to express GPC-1 include neurons, smooth and skeletal muscle cells, keratinocytes, osteoblasts, Schwann cells, immature dendritic cells, and tumor, plus tumor-associated vascular endothelial cells (8, 9, 12-15). The function of GPC-1 is complex and varied. As a proteoglycan, it appears to make use of its HS adduct to impact select growth factor activity (16). This is accomplished by having juxtramembrane HS attachment sites, and a flexible, GPI-linkage (17). Data suggests GPC-1 and sulfation enzymes may collaborate to regulate FGF signaling. HS modules that are rich in 2-O- and 6-O- sulfate upregulate FGF-2 activation of FGFR1c (18). Similarly, FGF-1 requires both 2-O- and 6-O-sulfation to bind to FGFR2c and 3c. By contrast, FGF-1 requires no sulfation to bind to FGFR2b, and FGF-8b needs only 6-O-sulfation to activate FGFR3c. Thus, many FGF receptor isoform specific effects may be attributed to an interaction between Glypican family members and the cell sulfation system (19).

**References:**

1. Song, H.H. and J. Filmus (2002) *Biochim. Biophys. Acta* **1573**:241.
2. Fransson, L.-A. *et al.* (2004) *Cell. Mol. Life Sci.* **61**:1016.
3. De Cat, B. and G. David (2001) *Semin. Cell Dev. Biol.* **12**:117.
4. Lamoureux, F. *et al.* (2007) *BioEssays* **29**:758.
5. Veugelers, M. *et al.* (1999) *J. Biol. Chem.* **274**:26968.
6. GenBank Accession # P35052.
7. David, G. *et al.* (1990) *J. Cell Biol.* **111**:3165.
8. Lories, V. *et al.* (1992) *J. Biol. Chem.* **267**:1116.
9. Lories, V. *et al.* (1989) *J. Biol. Chem.* **264**:7009.
10. GenBank Accession # EAW71184.
11. GenBank Accession # EAW71183.
12. Chernousov, M.A. *et al.* (2006) *J. Neurosci.* **26**:508.
13. Wegrowski, Y. *et al.* (2006) *Clin. Exp. Immunol.* **144**:485.
14. Qiao, D. *et al.* (2003) *J. Biol. Chem.* **278**:16045.
15. Kaye, H. *et al.* (2006) *Int. J. Oncol.* **29**:1139.
16. Selleck, S.B. (2006) *SciSTKE*, April **4**:pe17.
17. Qiao, D. *et al.* (2003) *J. Biol. Chem.* **278**:16045.
18. Su, G. *et al.* (2006) *Am. J. Pathol.* **168**:2014.
19. Allen, B.L. and A.C. Rapraeger (2003) *J. Cell Biol.* **163**:637.